Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer
M Sanford, LJ Scott - Drugs, 2009 - Springer
Gefitinib (Iressa™) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
that offers treatment for patients with locally advanced or metastatic non-small cell lung …
that offers treatment for patients with locally advanced or metastatic non-small cell lung …
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib …
Background Optimum management strategies for patients with advanced non-small-cell
lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are …
lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are …
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials
BACKGROUND: Gefitinib is an oral tyrosine kinase inhibitor against the epidermal growth
factor receptor (EGFR). It has been shown to be active in patients with advanced non-small …
factor receptor (EGFR). It has been shown to be active in patients with advanced non-small …
[HTML][HTML] Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus …
Abstract Objective The Phase III, randomized, open-label IPASS study (NCT00322452) of
first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) gefitinib …
first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) gefitinib …
Gefitinib alone versus gefitinib plus chemotherapy for non–small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study
Y Hosomi, S Morita, S Sugawara, T Kato… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with
cytotoxic chemotherapy is highly effective for the treatment of advanced non–small-cell lung …
cytotoxic chemotherapy is highly effective for the treatment of advanced non–small-cell lung …
[HTML][HTML] Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a …
S Watanabe, J Tanaka, T Ota, R Kondo, H Tanaka… - BMC cancer, 2011 - Springer
Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an …
T Mitsudomi, S Morita, Y Yatabe, S Negoro… - The lancet …, 2010 - thelancet.com
Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal
growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase …
growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase …
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
CK Lee, L Davies, YL Wu, T Mitsudomi… - JNCI: Journal of the …, 2017 - academic.oup.com
Background: We performed an individual patient data meta-analysis to examine the impact
of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) …
of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) …
Second‐line treatments after first‐line gefitinib therapy in advanced nonsmall cell lung cancer
JY Wu, JY Shih, CH Yang, KY Chen… - … journal of cancer, 2010 - Wiley Online Library
Gefitinib is effective as first‐line therapy for advanced nonsmall cell lung cancer (NSCLC).
However, after failure of gefitinib, it is unknown whether any second‐line regimens could …
However, after failure of gefitinib, it is unknown whether any second‐line regimens could …
Gefitinib for the treatment of non-small-cell lung cancer
T Hida, S Ogawa, JC Park, JY Park… - Expert review of …, 2009 - Taylor & Francis
Gefitinib is an orally bioavailable, EGF receptor tyrosine kinase inhibitor and was the first
targeted drug to be approved for non-small-cell lung cancer (NSCLC). Identification of …
targeted drug to be approved for non-small-cell lung cancer (NSCLC). Identification of …